nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

01.10.2012 | Reproductive Medicine

A macrophage activation marker chitotriosidase in women with PCOS: does low-grade chronic inflammation in PCOS relate to PCOS itself or obesity?

verfasst von: Ibrahim Alanbay, Cihangir Mutlu Ercan, Mehmet Sakinci, Hakan Coksuer, Mustafa Ozturk, Serkan Tapan

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Objective

Polycystic ovary syndrome (PCOS) is described as a low-grade chronic inflammatory state where the macrophage infiltration increased in visceral fat play the major role. The aim of this study was to assess chitotriosidase (ChT) activity (an activated macrophage marker) in women with PCOS and controls and to evaluate its correlation with anthropometric and biochemical parameters.

Study design

Seventy-nine women with PCOS and 60 healthy controls were included in the study. PCOS and controls were divided into two subgroups according to body mass indexes (BMIs) as normoweight (<25 kg/m²) and overweight (≥25 kg/m²). ChT activity, biochemical (free testosterone, luteinizing hormone, insulin resistance index, etc.) and clinical parameters [BMI, waist-to-hip ratio, modified Ferriman–Gallwey scores (mFG)] were analyzed according to groups.

Results

Serum ChT activity was significantly (p < 0.001) higher in women with PCOS than controls (normoweight, 87.1 ± 90.1 vs. 18.4 ± 9.0 nmol/ml/h; overweight, 92.0 ± 96.7 vs. 17.9 ± 12.1 nmol/ml/h PCOS and controls, respectively). No statistically significant difference was noted between ChT activity of normoweight and overweight PCOS subgroups. A positive correlation was found between ChT activity and PCOS status (r 0.598, p < 0.001), mFG scores (r 0.525, p < 0.001), free testosterone (r 0.402, p 0.001) and total testosterone (r 0.168, p 0.048) for the combined groups (PCOS + controls). In multivariant linear regression analysis participants’ PCOS status (presence or absence) and LH levels were the main predictors of ChT activity in the whole study population (p 0.002 and p 0.041, respectively).

Conclusion

ChT activity elevates in PCOS independent of obesity. Our findings support the concept of PCOS is a state of low-grade chronic inflammation where the macrophages could play the major role. Hyperandrogenism might also be related to this inflammatory state and can be a subject of further trials.

March WA, Moore VM, Wilson KJ, Phillips DIW, Norman RJ, Davies MJ (2010) The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 25:544–551PubMedCrossRef

Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R (2011) Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 7:219–231PubMedCrossRef

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF (2009) The androgen excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91:456–488PubMedCrossRef

Norman RJ, Dewailly D, Legro RS, Hickey TE (2007) Polycystic ovary syndrome. Lancet 370:685–697PubMedCrossRef

Katsikis I, Karkanaki A, Misichronis G, Delkos D, Kandaraki EA, Panidis D (2011) Phenotype expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod 156(2):181–185CrossRef

Doi SAR, Towers PA, Scott CJ, Al-Shoumer KAS (2005) PCOS: an ovarian disorder that leads to dysregulation in the hypothalamic–pituitary–adrenal axis? Eur J Obstet Gynecol Reprod 118:4–16CrossRef

Baptiste CG, Battista M-C, Trottier A, Baillargeon J-P (2010) Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol 122:42–52PubMedCrossRef

Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18:774–800PubMedCrossRef

Gilling-Smith C, Story H, Rogers S (1997) Evidence for a primary abnormality of theca cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol 47:93–99CrossRef

10.

Kelly CJ, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N (2001) Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86:2453–2455PubMedCrossRef

11.

Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B (2005) Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 90:6014–6021PubMedCrossRef

12.

Repaci A, Gambineri A, Pasquali R (2011) The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol 335:30–41PubMedCrossRef

13.

Barber TM, McCarthy MI, Wass JAH, Franks S (2006) Obesity and polycystic ovary syndrome. Clin Endocrinol 65:137–145CrossRef

14.

Kirchengast S, Huber J (2001) Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 16:1255–1260PubMedCrossRef

15.

Carmina E, Bucchieri S, Esposito A et al (2007) Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab 92:2500–2505PubMedCrossRef

16.

Yildirim B, Sabir N, Kaleli B (2003) Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil Steril 79(6):1358–1364PubMedCrossRef

17.

Glintborg D, Andersen M (2010) An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. Gynecol Endocrinol 26:281–296PubMedCrossRef

18.

Cascella T, Palomba S, De Sio I, Manguso F, Giallauria F, De Simone B, Tafuri D, Lombardi G, Colao A, Orio F (2008) Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. Hum Reprod 23:153–159PubMedCrossRef

19.

Cancello R, Cle′ment K (2006) Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. BJOG 113:1141–1147PubMedCrossRef

20.

Zeyda M, Stulnig TM (2007) Adipose tissue macrophages Immunology. Immunol Lett 112:61–67PubMedCrossRef

21.

Strissel KJ, Stancheva Z, Miyoshi H et al (2007) Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes 56:2910–2918PubMedCrossRef

22.

Heilbronn LK, Campbell LV (2008) Adipose tissue macrophages. Low grade inflammation and insulin resistance in human obesity. Cur Pharm Des 14:1225–1230CrossRef

23.

Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, Wang S, Fortier M, Greenberg AS, Obin MS (2005) Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46:2347–2355PubMedCrossRef

24.

Hollak CE, van Weely S, van Oers MH, Aerts JM (1994) Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93:1288–1292PubMedCrossRef

25.

Boot RG, Renkema GH, Strijland A, van Zonneveld AJ, Aerts JM (1995) Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J Biol Chem 270:26252–26256PubMedCrossRef

26.

Malaguarnera L (2006) Chitotriosidase: the yin and yang. Cell Mol Life Sci 63:3018–3029PubMedCrossRef

27.

The Rotterdam ESHRE/ASRM-Sponsored PCOS Conference Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25

28.

Ferriman D, Gallwey JD (1961) Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21:1440–1447PubMedCrossRef

29.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef

30.

Legro RS, Castracane VD, Kauffman RP (2004) Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 59:141–154PubMedCrossRef

31.

Escobar-Morreale HF, San Millán JL (2007) Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab 18:266–272PubMedCrossRef

32.

Lord J, Thomas R, Fox B, Acharya U, Wilkin T (2006) The central issue? Visceral fat is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. BJOG 113:817–824PubMedCrossRef

33.

Gesta S, Tseng YH, Kahn CR (2007) Developmental origin of fat: tracking obesity to its source. Cell 131:242–256PubMedCrossRef

34.

González F, Rote NS, Minium J, Weaver AM, Kirwan JP (2010) Elevated circulating levels of macrophage migration inhibitory factor in polycystic ovary syndrome. Cytokine 51:240–244PubMedCrossRef

35.

Gonzalez F, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P (1999) Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Metabolism 48:437–441PubMedCrossRef

36.

Escobar-Morreale HF, Luque-Ramırez M, Gonzalez F (2011) Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril 95:1048–1058PubMedCrossRef

37.

González F, Rote NS, Minium J, Kirwan JP (2006) Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 91:334–336

38.

González F, Rote NS, Minium J, Kirwan JP (2006) Increased activation of nuclear factor jB triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab 91:1508–1512PubMedCrossRef

39.

Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopus A, Katsikis I, Katsilambros N, Kraetsas G, Panidis D (2006) Indices of low- grade chronic inflammation in polycystic ovary syndrome and beneficial effect of metformin. Hum Reprod 21:1426–1431PubMedCrossRef

40.

Cortón M, Botella-Carretero JI, Benguría A, Villuendas G, Zaballos A, San Milla′n JL, Escobar-Morreale HF, Peral B (2007) Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. J Clin Endocrinol Metab 92(1):328–337PubMedCrossRef

41.

Möhlig M, Spranger J, Ristow M, Pfeiffer AF, Schill T, Schlösser HW, Moltz L, Brabant G, Schöfl C (2006) Predictors of abnormal glucose metabolism in women with polycystic ovary syndrome. Eur J Endocrinol 154:295–301PubMedCrossRef

Titel: A macrophage activation marker chitotriosidase in women with PCOS: does low-grade chronic inflammation in PCOS relate to PCOS itself or obesity?
verfasst von: Ibrahim Alanbay
Cihangir Mutlu Ercan
Mehmet Sakinci
Hakan Coksuer
Mustafa Ozturk
Serkan Tapan
Publikationsdatum: 01.10.2012
Verlag: Springer-Verlag
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 4/2012
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-012-2425-0

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

A macrophage activation marker chitotriosidase in women with PCOS: does low-grade chronic inflammation in PCOS relate to PCOS itself or obesity?